Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 321 staff and has a trailing 12-month revenue of around $23.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $172.36 |
|---|---|
| 52-week range | $168.67 - $172.46 |
| 50-day moving average | $160.97 |
| 200-day moving average | $97.64 |
| Wall St. target price | $172.40 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $172.36 from 2023-09-26
| 1 week (2024-08-27) | N/A |
|---|---|
| 1 month (2024-08-03) | N/A |
| 3 months (2024-06-03) | N/A |
| 6 months (2024-03-03) | N/A |
| 1 year (2023-09-07) | 1.30% |
|---|---|
| 2 years (2022-09-07) | 536.72% |
| 3 years (2021-09-07) | 53.65% |
| 5 years (2019-09-06) | 100.19% |
| Revenue TTM | $23.5 million |
|---|---|
| Gross profit TTM | $-167,627,000 |
| Return on assets TTM | -37.66% |
| Return on equity TTM | -112.39% |
| Profit margin | 0% |
| Book value | $2.31 |
| Market Capitalization | $6.6 billion |
TTM: trailing 12 months
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $168.67 up to $172.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.4194. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.